Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Leases (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Current Leases for 7 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 9.97% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, up 9.97% year-over-year, with the annual reading at $2.4 million for FY2025, 9.97% up from the prior year.
  • Current Leases for Q4 2025 was $2.4 million at Fulcrum Therapeutics, up from $2.3 million in the prior quarter.
  • The five-year high for Current Leases was $2.7 million in Q1 2023, with the low at $4000.0 in Q1 2021.
  • Average Current Leases over 5 years is $1.9 million, with a median of $2.2 million recorded in 2023.
  • Peak annual rise in Current Leases hit 990.7% in 2021, while the deepest fall reached 99.15% in 2021.
  • Over 5 years, Current Leases stood at $469000.0 in 2021, then surged by 454.8% to $2.6 million in 2022, then fell by 15.76% to $2.2 million in 2023, then dropped by 0.27% to $2.2 million in 2024, then grew by 9.97% to $2.4 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $2.4 million, $2.3 million, and $2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.